Sucampo, Gloria Pharmaceuticals deal

Sucampo granted Harbin Gloria exclusive rights to develop and commercialize Amitiza lubiprostone in China for 13 years. Sucampo will provide Gloria with Amitiza at an undisclosed supply price.

Sucampo will receive a $1 million upfront payment and is eligible for a $500,000 milestone payment upon approval of an IND for Amitiza in China and an undisclosed regulatory or commercial milestone. Gloria will be responsible for development and obtaining regulatory approval. Sucampo declined to provide further details, and Gloria could not be reached. ...